On November 7, 2024, Pacific Biosciences of California, Inc. (PacBio), a leading developer of high-quality, highly accurate sequencing solutions, announced that it entered into a privately negotiated exchange agreement with a holder of PacBio's remaining outstanding 1.50 percent convertible senior notes due 2028, pursuant to which PacBio will (i) issue $200 million principal amount of its 1.50 percent Convertible Senior Notes due 2029, (ii) issue 20,451,570 shares of PacBio's common stock, and (iii) make a cash payment in the amount of $50 million in exchange for $459 million principal amount of the 2028 Notes. The exchange transaction is expected to close on or about November 21, 2024, subject to customary closing conditions.

The Wilson Sonsini Goodrich & Rosati team representing PacBio on the transaction includes: